Press coverage about Mirati Therapeutics (NASDAQ:MRTX) has trended positive this week, Alpha One Sentiment reports. The research group, a division of Accern, identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with […]
